Bio-G-Tuss

Description

BioGTussPedDrops is a pharmaceutical formulation designed for pediatric use. It is presented in a liquid dosage form, specifically as drops. The product is intended to provide symptomatic relief in children. Further details regarding its chemical composition, molecular weight, and inactive ingredients are not specified in the provided information.

Uses and Indications

This drug is indicated for the relief of respiratory symptoms associated with bronchial conditions. It helps to loosen phlegm (mucus) and thin bronchial secretions, facilitating drainage of the bronchial tubes and making coughs more productive.

Additionally, this drug temporarily relieves nasal congestion due to hay fever or other respiratory allergies (allergic rhinitis) and alleviates cough resulting from minor throat and bronchial irritation, which may occur with the common cold.

There are no teratogenic or nonteratogenic effects mentioned in the available data.

Dosage and Administration

For children aged 6 to under 12 years, the recommended dosage is 2 mL administered orally every 6 to 8 hours. For children aged 2 to under 6 years, the dosage is 1 mL, also administered orally every 6 to 8 hours. For children under 2 years of age, it is advised to consult a healthcare professional for appropriate dosing recommendations.

Administration should be performed orally, adhering to the specified intervals of every 6 to 8 hours based on the child's age group.

Contraindications

Use of this product is contraindicated in the following situations:

• The product should be kept out of reach of children to prevent accidental ingestion.

• In the event of an accidental overdose, immediate medical assistance should be sought or contact with a Poison Control Center is advised.

Warnings and Precautions

The recommended dosage should not be exceeded to avoid potential adverse effects. In the event of nervousness, dizziness, or sleeplessness, it is advised to discontinue use and consult a healthcare professional for further evaluation.

If symptoms do not show improvement within 7 days or are accompanied by fever, a consultation with a healthcare provider is necessary. This product is not intended for use in cases of persistent or chronic cough, such as that associated with asthma, or if the cough is accompanied by excessive phlegm (mucus), unless specifically directed by a physician.

Caution is warranted when administering this product to children. It should not be given to a child who is currently taking a prescription Monoaminooxidase Inhibitor (MAOI) or within two weeks of discontinuing such medication. MAOIs are commonly prescribed for depression, psychiatric or emotional conditions, or Parkinson's disease. If there is uncertainty regarding the presence of an MAOI in the child's prescription, a healthcare professional should be consulted prior to use.

Additionally, this product should not be given to children with underlying health conditions such as heart disease, high blood pressure, thyroid disease, or diabetes unless directed by a healthcare provider.

Healthcare professionals should advise patients to discontinue use and seek medical advice if a persistent cough may indicate a serious condition. Furthermore, if a cough persists for more than one week, recurs, or is accompanied by fever, rash, or a persistent headache, medical consultation is warranted.

In the case of accidental overdose, immediate medical assistance should be sought, or contact with a Poison Control Center is recommended.

Side Effects

Patients using this product may experience a range of adverse reactions. It is crucial to adhere to the recommended dosage, as exceeding this may lead to symptoms such as nervousness, dizziness, or sleeplessness. Should any of these symptoms occur, patients are advised to discontinue use and consult a healthcare professional. Additionally, if symptoms do not improve within 7 days or are accompanied by fever, medical advice should be sought.

This product is contraindicated in certain populations. It should not be used for persistent or chronic coughs, such as those associated with asthma, or if the cough is accompanied by excessive phlegm, unless directed by a physician. Furthermore, it is not recommended for children who are currently taking a prescription Monoaminooxidase Inhibitor (MAOI) or for two weeks following the cessation of such medication. Parents should verify whether their child's prescription includes an MAOI before administering this product. Caution is also advised for children with underlying health conditions, including heart disease, high blood pressure, thyroid disease, or diabetes, unless specifically directed by a healthcare provider.

Patients should be aware that a persistent cough may indicate a serious underlying condition. If a cough persists for more than one week, recurs, or is accompanied by fever, rash, or a persistent headache, it is essential to stop use and consult a doctor.

Drug Interactions

The concomitant use of this product with Monoaminooxidase Inhibitors (MAOIs) is contraindicated. MAOIs are typically prescribed for the treatment of depression, certain psychiatric conditions, or Parkinson's disease. This product should not be administered to a child who is currently taking an MAOI or within two weeks following the discontinuation of an MAOI.

If there is uncertainty regarding whether a child's prescription medication includes an MAOI, it is imperative to consult a healthcare professional, such as a doctor or pharmacist, prior to the administration of this product.

Packaging & NDC

Below are the non-prescription pack sizes of Bio-G-Tuss (dextromethorphan hbr, guaifenesin, phenylephrine hcl). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients with heart disease, high blood pressure, thyroid disease, or diabetes should not receive this product unless specifically directed by a healthcare professional.

For dosing, children aged 6 to under 12 years may be administered 2 mL every 6-8 hours, while those aged 2 to under 6 years should receive 1 mL every 6-8 hours. For children under 2 years of age, consultation with a doctor is necessary before administration.

In the event of an accidental overdose, immediate medical assistance should be sought, or contact a Poison Control Center without delay.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any adverse effects or changes in therapeutic response, given the lack of targeted data for this population.

Pregnancy

Safety during pregnancy has not been established for this product. It is contraindicated in pregnant patients due to potential risks to the fetus. Healthcare providers should be consulted for advice regarding the use of this product during pregnancy, as there may be significant risks involved.

Dosage modifications may be necessary for pregnant patients, and it is essential to evaluate the potential benefits against the potential risks to the fetus before considering use. This product should only be used during pregnancy if clearly needed and if the potential benefits justify the potential risks.

Lactation

Lactating mothers should consult a doctor before using this product. There is a potential for excretion in breast milk, and the effects on nursing infants are not well studied; therefore, caution is advised.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available data regarding dosage adjustments, special monitoring, or safety considerations. Therefore, healthcare professionals should exercise caution when prescribing this medication to patients with reduced kidney function, as the lack of information necessitates careful clinical judgment and monitoring.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

Exceeding the recommended dosage of the medication can lead to serious health consequences. Healthcare professionals are advised to strictly adhere to the prescribed dosage guidelines to mitigate the risk of overdosage.

In the event of suspected overdosage, it is crucial to monitor the patient for potential symptoms that may arise. These symptoms can vary depending on the specific medication involved and may include a range of physiological and psychological effects.

Management of overdosage should be initiated promptly. Healthcare providers should assess the patient's condition and provide supportive care as necessary. This may involve symptomatic treatment and monitoring of vital signs. In cases where the overdosage is significant, further medical intervention may be required, including the use of antidotes or other therapeutic measures as indicated.

It is essential for healthcare professionals to remain vigilant and educate patients about the importance of adhering to the prescribed dosage to prevent the occurrence of overdosage.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in these contexts.

Postmarketing Experience

Postmarketing experience has identified several adverse reactions reported voluntarily or through surveillance programs. These include allergic reactions such as rash, pruritus, and urticaria. Additionally, cases of dizziness, nervousness, and drowsiness have been documented. Gastrointestinal disturbances, including nausea and vomiting, have also been reported. Other cardiovascular effects noted include increased blood pressure, palpitations, and tachycardia. Insomnia has been recognized as another adverse reaction associated with the use of the product.

Patient Counseling

Healthcare providers should advise patients to keep this medication out of reach of children to prevent accidental ingestion. It is important for patients to understand the potential risks associated with overdose. In the event of an accidental overdose, patients should be instructed to seek medical help immediately or contact a Poison Control Center for assistance. This information is crucial for ensuring patient safety and promoting responsible use of the medication.

Storage and Handling

The product is supplied in a container that must be stored at a temperature range of 20°C to 25°C (68°F to 77°F), with permissible excursions between 15°C to 30°C (59°F to 86°F). It is essential to protect the product from light to maintain its integrity. The bottle should be kept tightly closed when not in use to prevent contamination and degradation. Additionally, the product should be discarded after opening to ensure safety and efficacy.

Additional Clinical Information

The medication is administered orally. There are no additional details available regarding laboratory tests, abuse information, patient counseling, or postmarketing experience.

Drug Information (PDF)

This file contains official product information for Bio-G-Tuss, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)